May 29, 2019 06:12 AM EDT

Atara brings on Novartis vet to replace founder Ciechanover as chief

Natalie Grover

Reporter

After founding T-cell immunotherapy company Atara Biotherapeutics using Amgen $AMGN drug assets in 2012, Isaac Ciechanover made a surprise decision to leave the company this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Atara brings on Novartis vet to replace founder Ciechanover as chief

Natalie Grover

Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Investors pump $130M into protein degrader startup GlycoEra

Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Atara brings on No­var­tis vet to re­place founder Ciechanover as chief

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Atara brings on Novartis vet to replace founder Ciechanover as chief